Sunday, March 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

NBC opens Olympics with ‘worst hand imaginable’

Last year, NBC Sports executives called the Tokyo Olympics their most challenging undertaking ever.

Now that experience is starting to look like a cakewalk.

For this month’s Winter Games in Beijing, NBC confronts an even trickier mix of challenges, threatening to diminish one of the network’s signature products and one of the last major draws to broadcast television.

The list of headaches is long: an event nearly free of spectators, draining excitement from the arena and ski slopes; the threat of star athletes testing positive for Covid, potentially dashing their Olympic dreams; and the vast majority of its announcers, including Johnny Weir and Tara Lipinski, offering color commentary from a network compound in Stamford, Conn., instead of China.

The rising political tensions between the United States and China, including over China’s human rights abuses, add a troubling cloud to a typically feel-good spectacle.

Source: New York Times

https://www.nytimes.com/2022/02/03/business/media/olympics-nbc.html

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!